Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 514,365 American Depositary Shares of BioLineRx Ltd. as of September 30, 2026.

Key Highlights

  • Reporting persons: Armistice Capital, LLC (a Delaware entity) and Steven Boyd (United States) filed jointly as the reporting persons.
  • Beneficial ownership: Both reporting persons each disclosed aggregate beneficial ownership of 514,365 ADS, representing 9.99% of the class.
  • Voting and dispositive power: Both Armistice Capital and Steven Boyd report zero sole voting or dispositive power, with shared voting and shared dispositive power each at 514,365 ADS.
  • Direct holder: According to the filing, the ADS are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and investment advisory client of Armistice Capital.
  • Security type: The class of securities is American Depositary Shares, with each ADS representing six hundred ordinary shares, CUSIP 09071M304.
  • Triggering event date: The date of event requiring the filing was reported as September 30, 2026.

Armistice Capital and Boyd Disclose 9.99% Position in BioLineRx ADS

Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G on November 16, 2026, reporting beneficial ownership of BioLineRx Ltd. (NASDAQ:BLRX) American Depositary Shares. The filing states the triggering event occurred on September 30, 2026, with 514,365 ADS disclosed as beneficially owned, equaling 9.99% of the class. The securities are described as American Depositary Shares with each ADS representing six hundred ordinary shares, under CUSIP number 09071M304.

According to the filing, Armistice Capital serves as the investment manager of Armistice Capital Master Fund Ltd., which is identified as the direct holder of the shares. The filing states that "pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund." Steven Boyd, as managing member of Armistice Capital, is similarly described as potentially deemed to beneficially own these securities. The Master Fund "specifically disclaims beneficial ownership of the securities of the Issuer directly held by it" as a result of its Investment Management Agreement with Armistice Capital.

The filing further discloses that the Master Fund has the right to receive dividends from, or proceeds from the sale of, the reported securities. Neither Armistice Capital nor Steven Boyd reported any sole voting or sole dispositive power over the ADS. Both certify that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Armistice Capital, LLC and Steven Boyd jointly reported a 9.99% beneficial ownership position in BioLineRx Ltd. ADS, totaling 514,365 shares, through a Schedule 13G filed November 16, 2026, with a triggering event date of September 30, 2026.